Marksans Pharma Q4 FY26 Results: PAT Rs 149 Cr

Marksans Pharma Q4 FY26 results were declared on May 26, 2026. The company reported PAT of Rs 149 crore for the quarter ended March 31, 2026, up 63.7% YoY compared to Rs 91 crore in Q4 FY25. Revenue from operations was Rs 856 crore, up 20.9% YoY. Results are on a Consolidated basis. Marksans Pharma is a Generic Pharmaceuticals company listed on Indian stock exchanges.

Click Here – Get Free Investment Predictions

Marksans Pharma Q4 FY26 Financial Highlights

Note: Marksans Pharma Q4 FY26 results declared May 26, 2026. Data sourced from Screener.in BSE filings and verified news sources. Verify from audited statements before investment decisions.

Marksans Pharma Q4 FY26 Performance Analysis

The Marksans Pharma Q4 FY26 results reflect the company’s financial performance during the January to March 2026 quarter. Strong profitability growth of 63.7% YoY demonstrates improving operational execution. Marksans Pharma operates in the Generic Pharmaceuticals sector, supported by India’s GDP growth above 6.5% and domestic demand conditions in FY26.

Revenue of Rs 856 crore was up 20.9% YoY. Strong revenue growth reflects market expansion and demand.

Screen the best stocks on the Univest Screener.

Key Factors Driving Marksans Pharma Q4 FY26 Results

Revenue and Business Performance

Revenue of Rs 856 crore in Marksans Pharma Q4 FY26 was up 20.9% YoY. Double-digit revenue growth reflects strong demand and market share gains. The January to March quarter is the fiscal year-end period characterised by strong execution cycles across Indian companies.

Profitability and Margin Trends

the business PAT of Rs 149 crore up 63.7% YoY. Strong PAT growth demonstrates improving operational leverage.

India Macro Environment Q4 FY26

India’s macroeconomic environment in Q4 FY26 was supportive with GDP growth above 6.5%, government capex of Rs 11.21 lakh crore budgeted for FY27, and resilient domestic consumption. The RBI’s accommodative stance supported credit conditions. The Generic Pharmaceuticals sector benefited from these structural tailwinds during the January to March 2026 quarter.

FY27 Outlook

Following the firm results, management guidance on FY27 revenue growth, margin improvement roadmap, and capital allocation priorities will be key investor watchpoints. The Generic Pharmaceuticals sector continues to benefit from India’s long-term structural growth story. Sustaining the strong profitability momentum will be the primary FY27 focus.

Download the Univest iOS App or the Univest Android App to get daily stock recommendations and expert research.

Sector Performance and Peer Comparison

The Marksans Pharma Q4 FY26 results come at a time when Indian corporate earnings for Q4 FY26 reflect the strength of India’s domestic consumption story. Companies across sectors reported their January to March 2026 quarter results on May 26, 2026, providing investors with a comprehensive view of FY26 corporate performance. Marksans Pharma’s results contribute to this broader earnings picture. Indian equities have benefited from strong institutional investor participation, stable macro fundamentals, and a supportive RBI monetary policy environment during FY26, creating a positive backdrop for listed companies across market capitalisations.

Key Investor Takeaways from Marksans Pharma Q4 FY26

For investors tracking Marksans Pharma, the Q4 FY26 results provide important data points on revenue trajectory, profitability trends, and operational efficiency. Key metrics to evaluate include revenue growth sustainability, margin direction, working capital management, and debt levels. The company’s performance relative to its sector peers and its ability to deliver consistent shareholder returns in FY27 will be closely monitored. Management’s guidance on order book, capacity utilisation, and strategic priorities during the results discussion will shape near-term investor sentiment for Marksans Pharma shares.

Frequently Asked Questions on the company

Investments in securities are subject to market risk. This content is for educational purposes only. Verify all figures from BSE/NSE filings. Consult a SEBI-registered financial advisor.